Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | RBM15B | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-10 |
mRNA | FAM221A | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-10 |
mRNA | EHMT2 | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-10 |
mRNA | ARHGEF7 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-10 |
mRNA | HNRNPA0 | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-10 |
mRNA | ANGEL2 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-10 |
mRNA | RFX3 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-10 |
mRNA | ELAVL1 | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-10 |
mRNA | LMNB1 | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-10 |
mRNA | ZBED4 | CTRPv2 | pan-cancer | AAC | 0.24 | 4e-10 |